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Growth differentiation factor 15 (GDF-15), a marker of inflammation and oxidative stress, 
has emerged as a biomarker for arterial cardiovascular disease. However, the association 
between GDF-15 and venous thromboembolism (VTE) remains uncertain. We therefore 
investigated the association between plasma GDF-15 levels and future risk of incident VTE 
and explored the potential of a causal association using Mendelian randomization (MR). We 
conducted a population-based nested case-control study comprising 416 VTE patients and 
848 age- and sex-matched controls derived from the Tromsø Study. Logistic regression was 
used to calculate odds ratios (ORs) for VTE across GDF-15 quartiles. For the MR, we used 
data from the International Network on Venous Thrombosis (INVENT) consortium to 
examine whether single nucleotide polymorphisms (SNPs) associated with GDF-15 levels 
with genome-wide significance were related to VTE. We found that the ORs for VTE increased across GDF-15 quartiles 
(Ptrend 5 .002). Participants with GDF-15 values in the highest quartile (‡358 pg/mL) had an OR for VTE of 2.05 (95% 
confidence interval, 1.37-3.08) compared with those with GDF-15 in the lowest quartile (<200 pg/mL) in the age- and 
sex-adjusted model. ORs remained essentially the same after further adjustment for body mass index, smoking, 
hormone therapy, physical activity, and C-reactive protein. Similar results were obtained for provoked/unprovoked 
events, deep vein thrombosis, and pulmonary embolism. GDF-15 levels, as predicted by the SNPs, were not associated 
with VTE in MR. Our results indicate that high GDF-15 levels are associated with increased risk of VTE, but MR suggests 





Venous  thromboembolism  (VTE),  encompassing  deep  vein 
transforming growth factor b (TGF-b) superfamily.12  GDF-15 is 
recognized as a marker of oxidative stress, inflammation, and 
13-17 
thrombosis (DVT) and pulmonary embolism (PE), is a multicausal tissue  remodeling. It has  been  shown  to  be  a  biomarker 18 
disease, affecting 1 to 2 per 1000 individuals each year.1  VTE is for  risk  of  future  arterial  CVD and  for  thromboembolic  and 
associated with serious short- and long-term complications, 
including postthrombotic syndrome,  recurrence,  and  death.1,2 
In contrast to arterial cardiovascular disease (CVD), such as 
myocardial infarction (MI) and ischemic stroke, for which the 
incidence has declined during the last decades,3-5 the incidence 
of VTE has slightly increased during the same time period.6-8 It 
is likely that the incidence of VTE will continue to rise in the 
coming years because major risk factors for VTE such as ad- 
vancing age, obesity, and the incidence of cancer are in- 
creasing in the population.9-11 To reduce the health burden 
associated with VTE, novel biomarkers need to be identified 
and causal pathways that contribute to VTE pathogenesis must 
be  unraveled. 
 
Growth differentiation factor 15 (GDF-15), also known as mac- 
rophage  inhibitory  cytokine  1  (MIC-1),  is  a  member  of  the 
bleeding risk in patients with atrial fibrillation treated with an- 
ticoagulant therapy.19 Moreover, previous studies have shown 
increased plasma levels of GDF-15 in acute PE, and in patients 
with adverse outcome after PE.20,21 
 
In a small community-based cohort (Framingham Heart Study), 
higher levels of GDF-15 were associated with increased risk of 
future VTE.22 However, data on the association between GDF-15 
and VTE remains scarce,22 and the possible mechanisms un- 
derlying this association are unknown. For instance, the asso- 
ciation between GDF-15 levels and VTE may be explained by 
common factors (confounders) that are related to both GDF-15 
(exposure) and VTE (outcome). Inflammation and oxidative stress 
are linked to the pathogenesis of venous thrombosis,23,24 and 
these factors have been shown to induce GDF-15 expression in 
experimental studies.13,14,17  Thus, GDF-15 may simply be a risk 
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marker of VTE rather than a component in the causal path. Al- 
ternatively, GDF-15 may be causally related to VTE. If so, genetic 
variants that regulate GDF-15 levels are expected to be asso- 
ciated with VTE. Clarification of this question is worth pursuing 
from both mechanistic and clinical viewpoints because GDF-15 
could emerge as a potential new target for VTE prevention. First, 
we investigated the association between plasma levels of GDF- 
15 and the future risk of incident VTE and adjusted for high- 
sensitivity C-reactive protein (CRP), a sensitive and reliable 
downstream marker of inflammation. Second, we explored the 
potential association between GDF-15 and VTE from a causal 
perspective using a Mendelian randomization (MR) approach to 
examine whether genetically predicted levels of GDF-15 were 





Body height (to the nearest cm) and weight (to the nearest 0.5 kg) 
were assessed with participants wearing light clothing and no 
shoes.26 Body mass index (BMI) was calculated as weight divided 
by the square of height in meters (kg/m2). A self-administered 
questionnaire was used to collect detailed baseline information 
related to previous history of cancer and arterial CVD events (ie, 
MI, angina pectoris, transient ischemic attack, and stroke).27,28 
The questionnaire also included information on lifestyle factors, 
such as current daily smoking (pipe, cigar, or cigarettes), hor- 
mone therapy (estrogen supplementation or oral contracep- 
tives), and physical activity. Physical activity was dichotomized 
into regular physical activity ($1 hour per week) yes/no. 
Blood sample collection and storage of 
blood products 
Procedures for blood collection and storage of blood products 
Study population have  been  previously  described  elsewhere. 
27,28 Briefly, blood 
To address  the association between plasma levels of GDF-15 
and future risk of incident VTE, we used a nested case-control 
study derived from the Tromsø Study. The Tromsø Study is a 
single-center population-based cohort study, with repeated 
health surveys of inhabitants in Tromsø, Norway.25 All inhabitants 
age 25 years or older living in the municipality of Tromsø were 
invited to take part in the fourth survey of the Tromsø Study 
(Tromsø 4), carried out  in 1994-1995. A total of 27 158 indi- 
viduals participated, corresponding to 77% of those who were 
invited. Participants were followed from the inclusion date until 
the date of an incident VTE, migration, death, or end of follow-up 
(September 1, 2007).26 The identification of all first lifetime VTE 
events was performed by searching the hospital discharge di- 
agnosis registry, the autopsy registry, and the registry of ra- 
diologic procedures from the University Hospital of North 
Norway, which is the only hospital in the Tromsø region. Trained 
personnel performed extensive review of medical records to 
adjudicate each VTE event. An episode of VTE was confirmed if 
there were signs and symptoms consistent with DVT or PE in 
combination with objective confirmation by radiologic methods, 
leading to initiation of treatment, as previously described.26 A 
VTE event was classified as provoked when it occurred in the 
presence of 1 or more of the following provoking factors: ac- 
tive cancer, trauma or surgery (within 8 weeks before the 
event), acute medical conditions (acute ischemic stroke, acute 
MI, or acute infection), immobilization (bed rest for longer than 
3 days, confinement to a wheelchair within the past 8 weeks, 
or long distance travel  of  4  hours  or  longer  within  the  past 
14 days), or other factors specifically described as being pro- 
voked by a physician in the medical record (eg, intravascular 
catheter). 
 
A total of 462 individuals experienced a VTE event during the 
follow-up period (1994-2007), as described in Figure 1. For each 
case, 2 age- and sex-matched controls who were alive at the 
index date of the VTE event were randomly sampled from the 
source cohort (n 5 924), as previously described.27,28 In 46 cases 
and 76 controls, plasma samples of sufficient quality were not 
available for the analyses; consequently, our final analyses 
comprised 416 VTE cases and 848 controls. The regional 
committee for medical and health research ethics approved the 
study, and all study participants provided written informed 
consent. 
from participants who were not fasting was collected from an 
antecubital vein into 5-mL vacutainers (Becton Dickinson, Le 
Pont   de   Claix,   France)   containing   EDTA   (K3-EDTA   40   mL, 
0.37 mol/L per tube) as an anticoagulant at inclusion in Tromsø 4 
(1994-1995). Platelet-poor plasma was prepared by centrifu- 
gation at 3000g for 10 minutes at room temperature, after which 
the supernatant was transferred into cryovials (Greiner Labo- 
ratechnik, Nü rtringen, Germany) in 1-mL aliquots and stored at 
280°C until further analysis. 
 
Measurement of GDF-15, CRP, and hemostatic 
factors 
Plasma samples  were  thawed  at  37°C  in  a  water  bath  for 
5 minutes and prepared for analyses by centrifugation at 13 500g 
for 2 minutes to obtain platelet-free plasma.28  High-sensitivity 
CRP28 and GDF-15 plasma levels were measured in duplicates 
by enzyme-immunoassay (EIA) using commercially available 
reagents (R&D Systems, Minneapolis, MN) in a 384 format using 
the combination of a SELMA (Jena, Germany) pipetting robot 
and a BioTek (Winooski, VT) dispenser/washer (EL406). Ab- 
sorption was read at 450 nm with a wavelength correction set to 
540 nm using an EIA plate reader (Synergy H1 Hybrid, BioTek, 
Winooski, VT). The intra- and interassay coefficients of variation 
were 2.6% and 9.1%, respectively, for high-sensitivity CRP,28 and 
2.4% and 7.0% for GDF-15. Plasma levels of von Willebrand 
factor were measured by EIAs with antibodies (A0082, P02256) 
obtained from Dako (Glostrup, Denmark) using a polyclonal 
antibody for coating (A0082) and a horseradish peroxidase– 
conjugated polyclonal antibody for detection (P02256). Parallel 
diluted pooled human plasma was used as standard. D-dimer 
was measured by EIA using a monoclonal antibody (s4H9)29 for 
coating together with a monoclonal horseradish peroxidase– 
conjugated antibody for detection (ab24474, Abcam, Cambridge, 
United Kingdom). Parallel diluted samples of known concentration 
were used as standards. 
 
Statistical analysis 
Association between GDF-15 levels and VTE: the nested 
case-control study Statistical analyses were carried out using 
Stata version 15.0 (StataCorp, College Station, TX) and R version 
3.6.1 (The R Foundation for Statistical Computing, Vienna, 
Austria). GDF-15 was categorized according to quartile cutoffs 
determined in the control population (,200, 200-264, 264-358, 
$358  pg/mL).  Baseline  characteristics  across  quartiles  of 
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Plasma samples of 
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VTE cases 
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n = 924 
Figure 1. Flowchart of the study population. The flowchart illus- 
trates the nested case-control study derived from the fourth survey 



















GDF-15 were expressed as proportions for categorical variables 
and as mean (6 standard deviation [SD]) or median (25th-75th 
percentiles) for continuous variables. Logistic regression models 
were used to calculate odds ratios (OR) for VTE with 95% 
confidence intervals (CIs) according to quartiles of GDF-15. The 
lowest GDF-15 quartile was used as the reference category. The 
association between GDF-15 levels and VTE was adjusted for 
age and sex in model 1, for age, sex, BMI, smoking, hormone 
therapy, and physical activity in model 2, and CRP was added to 
model 3. We calculated the P value for linear trend for VTE risk 
across increasing quartiles of GDF-15. 
 
We performed subgroup analyses according to VTE location (ie, 
DVT and PE) and presence of provoking factors (ie, provoked 
and unprovoked VTE events). Arterial CVD and cancer are 
comorbidities associated with both GDF-15 levels18,30 and 
VTE.31-33 For sensitivity purposes, we evaluated the association 
between GDF-15 levels and overall VTE after excluding par- 
ticipants with self-reported history of cancer or arterial CVD 
events at baseline. Of note, D-dimer and von Willebrand factor 
are hemostatic factors reported to be associated not only with 
incident VTE34-36 but also with GDF-15 levels.37 To investigate 
whether these well-established VTE biomarkers could affect the 
association between GDF-15 levels and VTE, we added them to 
a fourth model as a sensitivity analysis. 
 
Our results based on only 1 measurement of GDF-15 could be 
subject to regression dilution bias because of the long follow-up 
time in the source cohort.38 To assess this question, analyses 
were performed by restricting the maximum follow-up time for 
the VTE cases while keeping all controls in the analyses.27,28 ORs 
were estimated at every 0.1-year increase in follow-up time and 
plotted as a function  of  this  maximum  time.  A  minimum  of 
10 VTE cases were required for the first estimation. 
 
MR We used an MR approach to investigate the association 
between GDF-15 levels and risk of VTE from a causal per- 
spective. MR is a method that uses genetic variants that are 
associated with modifiable exposures to assess causal re- 
lationship between exposures and diseases.39,40 MR relies on the 
fact that genotypes are randomly assigned at gamete formation, 
are generally independent of confounding, and are not influ- 
enced by disease processes.39,40 This way, MR is suitable for 
causal inference in observational studies. MR analysis requires 
estimates of the effect sizes of both the association between the 
single nucleotide polymorphisms (SNPs) and the exposure (ie, 
GDF-15 levels) and the association between the SNPs and the 
outcome (ie, VTE).41 In this study, we conducted a 2-sample MR 
analysis (ie, the SNP-exposure effects and the SNP-outcome 
effects were taken from 2 separate studies).41 To obtain the 
effect size of SNPs on GDF-15 levels, we used data from the 
largest available meta-analysis of genome-wide association 
studies of GDF-15 levels reported to date, with 5440 community- 
based white participants.42 In this meta-analysis, 9 SNPs on 
chromosome 19 were associated with GDF-15 blood concen- 
tration with genome-wide significance (ie, rs888663, rs3746181, 
rs1363120,   rs749451,   rs1054564,   rs1227731,   rs3195944, 
rs17725099, and rs16982345).42 For each of the 9 SNPs, effect 
size estimates and standard errors were extracted from the 
meta-analysis.42 Next, we used genome-wide association study 
summary data from the International Network on Venous 
Thrombosis (INVENT) consortium meta-analysis (7507 VTE cases 
and 52 632 controls)43 to obtain the effect size estimates of the 
association between these SNPs and VTE. The detailed in- 
formation on the 9 SNPs (eg, position on chromosome 19, lo- 
cation relative to the nearest gene, and minor allele frequency) is 
described in supplemental Table 1 (available on the Blood Web 
site), along with the effect size estimates and standard errors for 
the SNP-exposure association and the SNP-outcome association 
obtained from the meta-analysis42 and the INVENT consortium,43 
respectively. 
 
After filtering the 9 SNPs with a maximum linkage disequilibrium 
of 0.3, rs1054564, rs17725099, rs749451, and rs888663 SNPs 
were used in the final analysis (for details on linkage disequi- 
librium estimates, see supplemental Table 2). Of the 4 SNPs, 
 
rs888663 and rs17725099 are located in the downstream region 
of the pyroglutamyl-peptidase 1 (PGPEP1) gene, rs1054564 is 
located in the 39 untranslated region of GDF15, and rs749451 is 
located in the 39 untranslated region of PGPEP1 (supplemental 
Table  1).  The  4  SNPs  included  in  the  MR  analysis  explained 
;8.9% of the variance of GDF-15 blood concentration, as de- 
scribed in supplemental Table 1.The analysis was performed 
using the MR-Base framework.41 Causal-effect estimates of GDF- 
15 levels on VTE were obtained separately for each SNP, and to 
generate an estimate using all the SNPs, we used the inverse 
variance weighted method for primary analysis and MR-Egger 




Association between GDF-15 levels and VTE: the 
nested case-control study 
The distribution of baseline characteristics  across quartiles of 
GDF-15 levels is shown in Table 1. The mean age, median CRP 
levels, proportion of self-reported history of arterial CVD, and 
current smoking increased across quartiles of GDF-15, whereas 
the proportion of participants with regular physical activity de- 
creased. The sex distribution, mean BMI, proportion of partic- 
ipants with cancer, and current use of hormone therapy did not 
differ substantially across quartiles of GDF-15. 
 
The characteristics of the VTE patients are shown in Table 2. The 
mean age at the time of VTE was 67.6 6 13.7 years, and 48.1% 
were men. Among the VTE patients, 62.3% presented with DVT 
and 57.9% with provoked VTE events. The most common pro- 
voking factors were surgery or trauma (22.4%), cancer (21.4%), and 
immobilization (18.0%). 
Table 2. Characteristics of the VTE events (n 5 416) 
 
Characteristic Value 
Age at VTE, mean 6 SD, years 67.6 6 13.7 
Male sex, n (%) 200 (48.1) 
DVT, n (%) 259 (62.3) 
PE, n (%) 157 (37.7) 
Unprovoked VTE, n (%) 175 (42.1) 
Provoked VTE, n (%) 241 (57.9) 
Surgery or trauma, n (%) 93 (22.4) 
Cancer, n (%) 89 (21.4) 
Immobilization, n (%) 75 (18.0) 
Acute medical condition, n (%) 65 (15.6) 
Other factors, n (%) 17 (4.1) 
 
The ORs for VTE according to quartiles of plasma levels of GDF- 
15 are shown in Table 3. For overall VTE, the ORs increased 
across quartiles of GDF-15 in the age- and sex-adjusted model 
(Ptrend 5 .002). Individuals with plasma GDF-15 levels in the 
highest quartile ($358 pg/mL) had a 2.1-fold higher OR for VTE 
(OR, 2.05; 95% CI, 1.37-3.08) compared with those with GDF-15 
in the lowest quartile (,200 pg/mL). Risk estimates remained 
essentially the same after adding BMI, smoking, hormone 
therapy, and physical activity to model 2 (OR, 2.24; 95% CI, 1.46- 
3.43), as well as after further adjustment for CRP in model 3 (OR, 
2.07; 95% CI, 1.35-3.19). 
 















No. of participants 285 326 313 340 
Age, mean 6 SD, years 49 6 13 57 6 12 64 6 11 69 6 11 
Male sex, n (%) 137 (48.1) 166 (50.9) 144 (46.0) 147 (43.2) 
High-sensitivity CRP,    median (25th-75th 
percentile), mg/L 
0.93 (0.56-1.84) 1.18 (0.68-2.34) 1.49 (0.89-2.68) 1.90 (0.90-3.44) 
BMI, mean 6 SD, kg/m2 25.9 6 3.8 26.4 6 4.1 26.7 6 4.3 26.5 6 4.7 
Smoking, n (%) 67 (23.5) 92 (28.2) 104 (33.2) 131 (38.5) 
Hormone therapy, n (%) 19 (6.7) 20 (6.1) 14 (4.5) 7 (2.1) 
Physical activity, n (%)* 76 (26.7) 78 (23.9) 47 (15.0) 38 (11.2) 
Cancer, n (%)† 8 (2.8) 12 (3.7) 19 (6.1) 19 (5.6) 
Arterial CVD, n (%)‡ 13 (4.6) 46 (14.1) 54 (17.3) 87 (25.6) 
 
*Physical activity was defined as regular physical activity ($1 hour per week) at baseline. 
†Self-reported history of cancer at baseline. 
‡Self-reported history of arterial CVD (MI, angina, stroke) at baseline. 
 











OR (95% CI) 
















1 (reference) ,200 
200-264 213 113 1.63 (1.14-2.35) 1.67 (1.16-2.41) 1.63 (1.13-2.35) 
264-358 211 102 1.59 (1.08-2.36) 1.67 (1.12-2.51) 1.59 (1.06-2.39) 
$358 213 127 2.05 (1.37-3.08) 2.24 (1.46-3.43) 2.07 (1.35-3.19) 
















1 (reference) ,200 
200-264 213 73 1.74 (1.13-2.68) 1.75 (1.13-2.70) 1.70 (1.10-2.64) 
264-358 211 66 1.71 (1.07-2.72) 1.76 (1.09-2.85) 1.68 (1.04-2.73) 
$358 213 74 2.00 (1.23-3.26) 2.13 (1.28-3.54) 1.99 (1.19-3.33) 
















1 (reference) ,200 
200-264 213 40 1.48 (0.87-2.53) 1.54 (0.89-2.66) 1.49 (0.86-2.58) 
264-358 211 36 1.42 (0.79-2.54) 1.54 (0.85-2.80) 1.43 (0.78-2.62) 
$358 213 53 2.14 (1.19-3.86) 2.38 (1.29-4.39) 2.15 (1.16-4.00) 
















1 (reference) ,200 
200-264 213 71 1.93 (1.22-3.03) 1.96 (1.24-3.10) 1.92 (1.21-3.05) 
264-358 211 53 1.50 (0.91-2.48) 1.56 (0.94-2.61) 1.51 (0.90-2.52) 
$358 213 79 2.27 (1.36-3.78) 2.37 (1.40-4.02) 2.25 (1.32-3.84) 
















1 (reference) ,200 
200-264 213 42 1.32 (0.80-2.18) 1.33 (0.80-2.22) 1.29 (0.77-2.15) 
264-358 211 49 1.75 (1.03-2.95) 1.83 (1.07-3.16) 1.70 (0.98-2.95) 
$358 213 48 1.82 (1.05-3.17) 2.05 (1.15-3.66) 1.83 (1.02-3.30) 
Ptrend .024 .010 .033 
 
Model 1, adjusted for age and sex; Model 2, adjusted for age, sex, BMI, smoking, hormone therapy, and physical activity; Model 3, adjusted for age, sex, BMI, smoking, hormone therapy, 
physical activity, and high-sensitivity CRP. 
 
Similar to the overall analysis, GDF-15 levels were consis- 
tently associated  with VTE risk in  all  subgroups (ie, DVT, PE, 
provoked VTE, and unprovoked VTE) (Table 3). In the age- and 
sex-adjusted model, individuals with plasma GDF-15  levels  in 
the highest quartile had a 2.0-fold higher  OR  for  DVT  (OR, 
2.00; 95% CI, 1.23-3.26) and a 2.1-fold higher OR for PE (OR, 
2.14; 95% CI, 1.19-3.86) compared with those with GDF-15 in 
the lowest quartile. The ORs for the highest vs the lowest 
quartile of GDF-15 were 2.27 (95% CI, 1.36-3.78) for provoked 
VTE and 1.82 (95% CI, 1.05-3.17) for unprovoked VTE. As in 
the overall analysis, risk estimates  remained essentially the 
same in the subgroups after further adjustment for BMI, 
smoking, hormone therapy, physical activity, and CRP (Table 
3). In the sensitivity analyses, exclusion of participants with 
self-reported history of cancer (supplemental Table 3) and 
arterial CVD (supplemental Table 4) at baseline yielded results 
similar to those in the main analysis. Supplemental Table 5 
shows that even after additional adjustment for D-dimer and 
von Willebrand factor (model 4), GDF-15 levels remained 
consistently associated with VTE, with an OR of 2.00 (95% CI, 
1.29-3.11)  for  the  highest  versus  the  lowest  quartile  (Ptrend 
across quartiles 5 .007). 
 
To investigate the possibility of underestimating ORs as a result 
of regression dilution bias, we estimated ORs for VTE among 
individuals with high (highest quartile) vs low (lowest quartile) 
plasma GDF-15 as a function of time between blood sampling 
and VTE events. As shown in Figure 2, the ORs for VTE by high 
levels of GDF-15 were substantially higher with shortened time 
between blood sampling and VTE events. 
 
MR 
Causal-effect estimates of GDF-15 levels on VTE using MR 
analysis are  shown in Figure 3.  Genetically predicted GDF-15 
levels were not associated with VTE in analyses for each of the 
individual SNPs: rs888663  (log-odds  per  SD,  0.106;  95% 
CI, 20.082 to  0.294), rs17725099 (log-odds per  SD, 0.089; 
95% CI, 20.233 to 0.412), rs749451 (log-odds per SD, 20.052; 95% 
CI, 20.261 to 0.156), and rs1054564 (log-odds per SD, 20.124; 
95% CI, 20.347 to 0.099). When the 4 SNPs were combined, 
 
at baseline. In contrast, when using an MR approach, genetically 
predicted GDF-15 plasma levels were not associated with VTE. 
Our findings suggest that GDF-15 is not causally related to VTE, 
but GDF-15 may still be relevant as a biomarker to help improve 






















Figure 2. Plots of estimated ORs for overall VTE as a function of time from blood 
sampling in Tromsø 4 (1994-1995) to VTE events. Participants with plasma GDF-15 
levels in the highest quartile (Q4) were compared with those with GDF-15 levels in the 
lowest quartile (Q1, reference category). Analyses were adjusted for age, sex, BMI, 
smoking, hormone therapy, physical activity, and high-sensitivity CRP. Large, solid 
circles indicate ORs with P , .05. The number of VTE events are depicted above the 
plot. Note that because of a missing value in BMI, there were 415 VTE events when 
BMI was used as an adjustment variable. 
 
 
no association of GDF-15 with VTE was detected in inverse 
variance–weighted  analysis  (log-odds  per  SD,  0.002;  95%  CI, 
20.109 to 0.113) and MR-Egger analysis (log-odds per SD, 20.030; 




In this nested case-control study derived from the general 
population, we found that the risk of VTE increased with in- 
creasing levels of GDF-15. Participants with GDF-15 levels in the 
highest quartile had a twofold higher OR for VTE than those with 
GDF-15 in the lowest quartile in analyses adjusted for age and 
sex. The risk estimates remained essentially the same after 
further adjustment for potential confounders, including BMI, 
lifestyle factors (ie, smoking, hormone therapy, and physical 
activity) and CRP. Similar results were obtained for DVT, PE, and 
provoked and unprovoked VTE events, and after excluding 
participants with self-reported history of cancer and arterial CVD 
GDF-15 has emerged as a biomarker in several diseases, in- 
cluding arterial CVD, heart failure, and cancer. For instance, 
higher levels of GDF-15 have been associated with increased risk 
of future cardiovascular events in the community and in patients 
with coronary artery disease, and with adverse outcomes among 
those with heart failure.18 Moreover, increased GDF-15 has been 
associated with various types of cancer,30 kidney disease,45 and 
inflammatory disorders, such as rheumatoid arthritis.46 In the 
ARISTOTLE trial, GDF-15 was associated with major bleeding 
and death in patients with atrial fibrillation who were receiving 
oral anticoagulation.19 Although GDF-15 is weakly expressed in 
human tissue during normal conditions,14 GDF-15 seems to be 
expressed and secreted in response to inflammation,14,17 oxi- 
dative stress,13,17 and hypoxia,17 reflecting its potential as a 
biomarker for development and progression of a wide range of 
disorders. 
 
In contrast to arterial CVD, the association between plasma GDF- 
15 levels and VTE has not been thoroughly investigated. The 
predictive ability of 12 biomarkers was assessed in the Fra- 
mingham Heart Study, a cohort consisting of 3120 participants, 
of whom 139 developed an incident VTE during a median follow- 
up of 16 years.22 Among the tested biomarkers, GDF-15 and 
D-dimer were individually associated with VTE in multivariable- 
adjusted analyses. In our nested case-control study derived from 
a population-based cohort, we extended previous findings by 
identifying GDF-15 as a global biomarker for VTE of similar effect 
size irrespective of the presence of provoking factors and lo- 
cation of the VTE event (ie, DVT or PE). 
 
To the best of our knowledge, this study is the first to address the 
relationship between GDF-15 levels and VTE from a causal point 
of view. In our observational study, causality was assessed by 
using genetic variants and applying MR, thus avoiding con- 
founding and reverse causation.39,40 By using a group of 4 SNPs 
associated with GDF-15 levels on a genome-wide significant 
level,42 we found that genetically predicted GDF-15 levels were 
not associated with VTE. This finding suggests that GDF-15 is not 
causally related to VTE but it is simply a risk marker for VTE. 










Figure 3. Forest plot of the MR analysis. Forest plot of the 
MR analysis with point estimates (log-odds per SD of GDF-15) 
and 95% CIs of causal effect of GDF-15 levels on VTE for each 
SNP and collectively (ie, inverse variance–weighted analysis 
and MR-Egger) in regression analyses. 
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considerably higher with shortened time between blood sam- 
pling and the thrombotic events, reinforce the notion that GDF- 
15 is a modifiable biomarker. Still, it is important to address that 
even when blood samples were collected several years before 
the thrombotic event, GDF-15 levels remained significantly 
associated with VTE, a finding that underscores the potential of 
GDF-15 as a reliable biomarker for VTE. To clarify the clinical 
utility of GDF-15 as a biomarker for VTE, assessment of the 
association between GDF-15 and VTE after adjustment for well- 
established VTE biomarkers would be an important step. In- 
terestingly, we found that the association between GDF-15 
levels and VTE was essentially independent of D-dimer and von 
Willebrand factor, which are well-known biomarkers for incident 
VTE.34-36 This finding suggests that GDF-15 could be a useful 
biomarker for improving risk stratification for VTE in the clinic 
that would guide decision-making on VTE prevention together 
with other relevant biomarkers using a multimarker approach. 
 
A noteworthy finding of this study was the fact that inflammation 
did not seem to explain the relationship between GDF-15 levels 
and VTE, because adjustment for CRP had a negligible effect on 
the risk estimates. Because GDF-15 has also been regarded as a 
marker of oxidative stress,13,17 oxidative stress could be relevant 
for the association between GDF-15 and VTE. Accordingly, 
experimental data have shown that hydrogen peroxide en- 
hanced venous thrombosis susceptibility in aged mice.24 Further 
studies are warranted to confirm our findings on the association 
between plasma GDF-15 levels and VTE and reveal underlying 
mechanisms for this association. 
 
Strengths of our study  include the nested case-control study 
design, in which the VTE cases were selected from a population- 
based cohort, and the age- and sex-matched controls were 
selected from the same source population. Because of the 
prospective nature of this study, it was possible to make as- 
sumptions on  the temporal sequence  between exposure and 
outcome. Some limitations of the study need to be mentioned. 
The blood samples in which the analysis of GDF-15 was per- 
formed were drawn in 1994-1995 and were stored at 280°C for 
up to 22 years. The long storage time could potentially affect the 
plasma levels of GDF-15. Nevertheless, it is unlikely that this 
would change the results, because a storage effect on plasma 
samples would be similar in VTE cases and controls. In addition, 
plasma GDF-15 was measured solely at baseline, and changes in 
GDF-15 levels during follow-up (up to 12 years) could have 
resulted in underestimation of the true association because of 
regression dilution.38 Although ORs for VTE according to plasma 
GDF-15 decreased with prolonged time between blood sam- 
pling and the  thrombotic event, risk  estimates remained  sig- 
nificant during the entire follow-up period. Chronic kidney 
disease is associated with GDF-15 levels45 and VTE47 and could 
act as a potential confounder for the association between GDF- 
15 and VTE. Unfortunately, information on estimated glomerular 
filtration rate and albuminuria (variables used to define chronic 
kidney disease) was available in only a limited number of par- 
ticipants from Tromsø 4, and therefore we could not take chronic 
kidney disease into account in our regression analyses. In this 
study, the great majority of participants were white, and caution 
is warranted when extrapolating our findings to other ethnicities. 
Finally, the limitations of an MR approach40,41 should be con- 
sidered when interpreting our results. 
 
In conclusion, our results indicate that high plasma GDF-15 
levels are associated with increased risk of VTE. Our findings on 
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